VanEck Biotech ETF (NASDAQ:BBH) Shares Up 0.6% – Here’s Why

VanEck Biotech ETF (NASDAQ:BBH) shares traded up 0.6% during mid-day trading on Tuesday . The company traded as high as $212.54 and last traded at $211.57. Approximately 5,331 shares were traded during mid-day trading, an increase of 5% from the average daily volume of 5,064 shares. The stock had previously closed at $210.33.

VanEck Biotech ETF Trading Up 0.4%

The business’s fifty day simple moving average is $190.26 and its two-hundred day simple moving average is $191.32.

Institutional Investors Weigh In On VanEck Biotech ETF

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of VanEck Biotech ETF by 40,463.3% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 494,061 shares of the company’s stock valued at $93,506,000 after purchasing an additional 492,843 shares during the last quarter. Raymond James Financial Inc. boosted its position in shares of VanEck Biotech ETF by 2.8% in the 3rd quarter. Raymond James Financial Inc. now owns 69,809 shares of the company’s stock valued at $11,566,000 after purchasing an additional 1,869 shares during the period. Bank of America Corp DE grew its stake in VanEck Biotech ETF by 44.3% during the 1st quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock worth $12,473,000 after buying an additional 20,375 shares during the last quarter. Ascent Advisors LLC purchased a new position in VanEck Biotech ETF during the 1st quarter worth approximately $11,178,000. Finally, LPL Financial LLC increased its position in VanEck Biotech ETF by 63.5% during the fourth quarter. LPL Financial LLC now owns 31,813 shares of the company’s stock worth $6,021,000 after buying an additional 12,351 shares during the period. 32.05% of the stock is currently owned by institutional investors and hedge funds.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.